Altimmune AI Price Prediction

The negative EPS and resulting negative P/E ratio indicate Altimmune is currently loss-making with no clear profitability support for the current valuation. Without evidence of improving earnings trends or a path to positive cash flow, the financial profile remains speculative and dependent on future pipeline success rather than current fundamentals.

• Negative EPS of -0.78 implies ongoing losses and lack of current earnings support for equity holders.
• A P/E ratio of -4.10 confirms the company is not profitable and investors are effectively paying for future potential rather than present earnings.
• In the absence of positive earnings or profitability ratios, the risk profile is elevated and the stock is highly sensitive to clinical, regulatory, or funding news.

Despite a 9.6% gain over the last month, Altimmune’s share price at $3.20 remains below its 200-day moving average of $3.69, indicating the longer-term trend is still weak. The recent bounce looks more like a short-term recovery within a broader downtrend rather than a confirmed reversal.

• Current price of $3.20 trades below the 200-day moving average of $3.69, a classic sign of a prevailing longer-term downtrend.
• A 9.6% one-month gain suggests short-term positive momentum, but not yet enough to break above key long-term resistance (the 200-day MA).
• With negative earnings and price below the 200-day MA, the technical picture remains fragile and vulnerable to downside if sentiment weakens.

Altimmune’s stock remains fundamentally speculative, with negative earnings and a share price that still trades below its 200-day moving average despite a recent short-term bounce. Alternative data are mixed but not strong enough to counterbalance the weak profitability profile and cautious technical setup, leading to an overall bearish stance.

• Negative EPS and a negative P/E ratio underscore a lack of current profitability, leaving the stock highly dependent on future execution and clinical milestones.
• Trading below the 200-day moving average with only modest alternative data strength supports a bearish overall view, with the recent price uptick looking more like a short-term rally than a confirmed trend reversal.